Europe Immunohematology Market size exceeded USD 650 million in 2021 and is anticipated to exhibit a CAGR of 4% from 2022 to 2028. The growing number of blood transfusions is driving product adoption, thanks to the higher frequency of road accidents. With trauma injuries becoming more common across metropolitan cities in Europe, companies are witnessing more demand from private and publicly funded diagnostic labs and hospitals.

Get more details on this report - Request Free Sample PDF

Several awareness programs related to blood donation across the globe will have a positive influence on the market size, as governments are installing more hematology devices across state-run diagnostic facilities. The World Health Organization (WHO) has organized programs like ‘Blood and Transfusion Safety’ to support national blood systems to maintain timely access to the supply of blood and blood products.

COVID-19 impact on Europe immunohematology industry

The COVID-19 outbreak in the region has significantly impacted the industry owing to disruptions in healthcare services. Procedures like blood transfusions were halted or delayed due to the fear of the virus spreading through blood. Storing of blood was a major issue at the beginning of the pandemic as the number of patients in each hospital was more than the beds. During this time, several rules and regulations were also levied by authoritative bodies to limit the virus spread, preventing the market growth.

On the upside, increasing number of studies examining the blood of recovered patients treated with plasma and antibody therapies is fostering product use. As people get better clarity regarding the importance of plasma therapy, blood donation, transfusions, and other blood work, industry participants will leverage the upcoming opportunities from new trends.

Europe Market, By Product

The analyzers and systems segment revenue will surpass USD 280 million by 2028, attributed to the increasing requirement for high-throughput automatic analyzer systems. Solution providers are developing new and innovative automated systems for streamlining operations of healthcare service providers. Amidst expanding patient footfall since the pandemic, these establishments are more inclined toward products that reduce the turnround time of test results.

Over the next few years, more automated technologies targeting varying medical conditions are likely to enter the market. Recently, Sysmex America received FDA clearance for its XN-10 Automated Hematology Analyzer with Blood Bank mode. This device will support the red blood cell, residual WBC counting, and platelet component testing all in a single sample aspiration.

Europe Market, By Technology

The gel card technology segment will hold more than 28% Europe immunohematology market share by 2028. Antigen detection, cross-matching, and alloantibody identification are easily possible using gel card systems. Interpretive errors can be easily avoided using these systems, as they are quite efficient. One key advantage offered by these solutions is that they minimize dependence on human operators, as they do not need skilled professionals.

The routine tests that are performed in blood banks are simplified with gel-card technology. Due to their wide applications, blood banks are adopting such technologically advanced blood serology techniques which will influence the market revenue. With the number of blood banks in low- and middle-income countries in Asia on the rise, the industry forecast appears to be optimistic.

Competitive Industry Landscape

Prominent participants operating across the market include Roche Diagnostics, Beckman Coulter, Grifols, Abbott, Bio-Rad Laboratories, Siemens Healthcare, ANTISEL S.A., Thermo Fisher Scientific, and Becton Dickinson. To bridge the gap between demand and supply in the market, these top companies are adopting several strategies, initiatives, mergers, product launches, and acquisitions.